intermittent claudication
Cardiovascular · 2009–2010
Every decision here pre-dates the consumer comments facility, so no input would be recorded either way.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| cilostazol Symptomatic improvement of intermittent claudication as indicated by increased maximal and pain-free walking distances in patients who do not have rest pain… | Jul 2010 | Not recommended | no section in document |
| cilostazol Symptomatic improvement of intermittent claudication as indicated by increased maximal and pain-free walking distances in patients who do not have rest pain… | Jul 2009 | Not recommended | no section in document |
Appraised elsewhere
NICE, in England and Wales, has appraised 1 technology for this condition, recommending 0 and declining 1. A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| cilostazol naftidrofuryl oxalate pentoxifylline and inositol nicotinateCilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease | TA223 | not recommended | 2011-05 |
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| pentoxifyllineTRENTAL 400 pentoxifylline (oxpentifylline) 400 mg modified release ta | 2001 | 1 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 0 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.